Search

Displaying results 2351 - 2360 of 9324 in total
  1. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. … increasing the signalling of other neurotransmitters in the brain.

  2. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    Although the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK … [A256758] Unlike BTK covalent inhibitors, such as [ibrutinib], that bind to the cysteine 481 (Cys481) amino acid within the active site of BTK, the inhibitory activity of pirtobrutinib is maintained even

  3. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Ombitasvir as a first line … Depending on the genotype, Ombitasvir is often used in combination with other antivirals such as [DB09183], [DB09297], [DB00503], and [DB00811] with the intent to cure, or achieve a sustained virologic

  4. Drug

    Gemfibrozil

    go.drugbank.com/drugs/DB01241
    ApprovedInvestigational

    Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias. … [A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.

  5. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    [A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

    Products: ZELBORAF ® TABLETAS LACADAS DE 240 MG
  6. Drug

    Tadalafil

    go.drugbank.com/drugs/DB00820
    ApprovedInvestigational

    In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment … [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH.

  7. Drug

    Deferasirox

    go.drugbank.com/drugs/DB01609
    ApprovedInvestigational

    Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

  8. Drug

    Chlormezanone

    go.drugbank.com/drugs/DB01178
    ApprovedWithdrawn

    A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.

  9. Drug

    Ibalizumab

    go.drugbank.com/drugs/DB12698
    ApprovedInvestigational

    the lymphocytes. … In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448]

  10. Drug

    Aminosalicylic acid

    go.drugbank.com/drugs/DB00233
    ApprovedInvestigational

    The sodium salt of the drug is better tolerated than the free acid.